Table 2.
Exposure to study drug (received doses).
| Placebo (n = 1262) | Lasmiditan 50 mg (n = 654) | Lasmiditan 100 mg (n = 1265) | Lasmiditan 200 mg (n = 1258) | Lasmiditan pooled doses (n = 3177) | |
|---|---|---|---|---|---|
| One dose only, n, (%) | 500 (40) | 352 (54) | 716 (57) | 802 (64) | 1870 (59) |
| Two dosesa, n, (%) | 762 (60) | 302 (46) | 549 (43) | 456 (36) | 1307 (41) |
| Placebo | 762 | 96 | 169 | 153 | |
| Active | – | 206 | 380 | 303 |
a
Second dose taken for rescue (patient did not achieve headache pain-free status at 2 hours, completed the 2-hour assessments, and took a second dose of study drug between 2 and 24 hours post-first dose) or recurrence (patient achieved headache pain-free status at 2 hours but then experienced recurrence of mild, moderate, or severe migraine pain and took a second dose of study drug up to 24 hours after the first dose).